$205.29 Million in Sales Expected for BioScrip, Inc. (BIOS) This Quarter
Equities analysts expect BioScrip, Inc. (NASDAQ:BIOS) to report sales of $205.29 million for the current quarter, according to Zacks. Four analysts have made estimates for BioScrip’s earnings, with the highest sales estimate coming in at $209.77 million and the lowest estimate coming in at $202.09 million. BioScrip reported sales of $224.54 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 8.6%. The firm is expected to issue its next earnings report on Monday, November 6th.
According to Zacks, analysts expect that BioScrip will report full year sales of $205.29 million for the current fiscal year, with estimates ranging from $819.83 million to $829.80 million. For the next year, analysts expect that the firm will post sales of $769.09 million per share, with estimates ranging from $728.39 million to $814.89 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for BioScrip.
BioScrip (NASDAQ:BIOS) last released its earnings results on Tuesday, August 8th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.10) by $0.01. The business had revenue of $218.11 million during the quarter, compared to analysts’ expectations of $220.05 million. The firm’s revenue was down 6.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.14) earnings per share.
BIOS has been the topic of several research reports. Zacks Investment Research downgraded BioScrip from a “hold” rating to a “sell” rating in a research report on Wednesday, May 10th. Barrington Research upped their target price on BioScrip to $3.50 and gave the company an “outperform” rating in a research report on Monday, June 26th. ValuEngine raised BioScrip from a “sell” rating to a “hold” rating in a research report on Thursday, July 13th. BidaskClub downgraded BioScrip from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 1st. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $4.00 target price (up previously from $3.00) on shares of BioScrip in a research report on Thursday, August 10th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company has an average rating of “Buy” and an average price target of $3.75.
BioScrip (NASDAQ:BIOS) traded down 4.462% during mid-day trading on Tuesday, reaching $3.105. The company’s stock had a trading volume of 1,377,970 shares. The stock’s market cap is $395.81 million. BioScrip has a 52-week low of $0.98 and a 52-week high of $3.43. The company has a 50 day moving average of $2.86 and a 200-day moving average of $2.06.
Several institutional investors have recently bought and sold shares of BIOS. Goldman Sachs Group Inc. increased its position in BioScrip by 65.8% in the first quarter. Goldman Sachs Group Inc. now owns 64,257 shares of the company’s stock valued at $109,000 after buying an additional 25,500 shares during the last quarter. American International Group Inc. increased its position in BioScrip by 73.8% in the first quarter. American International Group Inc. now owns 67,812 shares of the company’s stock valued at $115,000 after buying an additional 28,787 shares during the last quarter. Captrust Financial Advisors purchased a new position in BioScrip during the second quarter valued at approximately $123,000. Voya Investment Management LLC increased its position in BioScrip by 41.4% in the second quarter. Voya Investment Management LLC now owns 50,799 shares of the company’s stock valued at $138,000 after buying an additional 14,867 shares during the last quarter. Finally, Alambic Investment Management L.P. purchased a new position in BioScrip during the first quarter valued at approximately $160,000. 85.62% of the stock is currently owned by institutional investors.
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with MarketBeat.com's FREE daily email newsletter.